Pharmaceuticals
- Article Tools
- Email this Article
- Print this Article
- Rss Feed
- Related Articles
- Sanofi Yanks Obesity Drug Application
- Sanofi's Prospects Get Leaner
- Why Sanofi-Aventis Must Buy Bristol-Myers
- Serious Setback for Sanofi
- Sanofi Drug Has Suicide Risk
- Sanofi-Aventis Boosts Outlook
- Del.icio.us
- Digg
- StumbleUpon
A weight-loss drug from Sanofi-AventisSNY took another hit Thursday when European health regulators said people with depression shouldn't use the drug. Known as Acomplia in Europe, where it was approved 13 months ago, the obesity treatment was unanimously opposed by an advisory panel to the U.S. Food and Drug Administration last month. Advisors were concerned that the drug, whose U.S. brand name is Zimulti, would cause psychiatric side effects. The FDA was scheduled to vote on the drug in July, but it didn't get the chance. On June 29, Sanofi-Aventis withdrew its application, adding that it is "committed to taking all steps necessary" to make the drug available. The U.S. has been viewed by Sanofi-Aventis and by analysts as the key to achieving peak annual sales that some had forecast as high as $3 billion. The drug is approved in 37 countries and sold in 18, including large EU markets such as France, Germany and the U.K. On Thursday, the FDA's counterpart in the EU said Acomplia shouldn't be prescribed for people "with ongoing major depression or who are being treated with antidepressants, because of the risk of psychiatric side effects." The European Medicines Agency's proposal has been sent for a vote by the EU's governing body.
Zimulti might be resubmitted.
The stock falls a day after an FDA panel says a weight-loss drug shouldn't be sold in the U.S.
Holding Bristol and waiting for the fireworks here might pay off.
An FDA panel says a weight-loss drug should be denied approval.
The FDA staff says Acomplia increases the chance of psychiatric problems.
First-quarter profits slip.
Yahoo! is among the most searched stocks on TheStreet.com. Here's what Cramer had to say about the stock recently.
Catch up on his thinking on the hottest topics of the past week.
Investors will have to deal with a Fed meeting and another flood of earnings and economic data.
Ensco International and Echelon have the potential to move higher in coming days.
See who made what calls.
The addition of video is helping telecom companies compete against cable and satellite companies.
The June West Texas Intermediate contract reflects selling pressure ahead of Tuesday's expiration. But stocks in the sector are generally trading higher.
See who made what calls.
Keep on top of the market and the critical information you need to make more profitable investing decisions.
Sponsored by:
RSS
